Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improved Survival of Advanced-Stage Anaplastic Thyroid Cancer With Systemic Therapy.

The Laryngoscope - 1 Jan 2025

Evans Lauran K, Chen Haidee, Taki Labib Manwel, Cronkite D Alexander, Yu Alice C, Ashendouek Maya, Elashoff David, Chai-Ho Wanxing, Wong Deborah J, St John Maie

Abstract excerpt

OBJECTIVES: Anaplastic thyroid cancer (ATC) is the most aggressive and fatal thyroid malignancy. Currently, there still exists a paucity of literature studying the relationship between available ATC-targeted therapy, immunotherapy, and survival. We aim to investigate how systemic therapies affect survival outcomes in ATC. METHODS: A single-tertiary-institution chart review of patients diagnosed with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pyrimidinones
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Molecular Targeted Therapy

Share to Oximes

Share to Pyridones

Share to Thyroid Carcinoma, Anaplastic

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 39162326
DOI: 10.1002/lary.31712
PMCID: PMC11635144

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improved Survival of Advanced-Stage Anaplastic Thyroid Cancer With Systemic Therapy.PMID 39162326Read ↗

Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial.Semantic proximity Read ↗

Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease.Semantic proximity Read ↗

Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort.Semantic proximity Read ↗

Personalized treatment of 95 poorly differentiated thyroid cancer/anaplastic thyroid cancer in 2019-2023.Semantic proximity Read ↗

Characterization of Advanced RAS-driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues.Semantic proximity Read ↗

Anlotinib Plus Sintilimab for BRAFV600E Negative Unresectable or Metastatic Anaplastic Thyroid Carcinoma: A Single-Center, Single-Arm, Phase 2 Trial.Semantic proximity Read ↗

Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.Semantic proximity Read ↗

Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.Semantic proximity Read ↗

Evaluating new treatments for anaplastic thyroid cancer.Semantic proximity Read ↗

Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.Semantic proximity Read ↗

Recent advances in anaplastic thyroid cancer management.Semantic proximity Read ↗

Untitled literature recordSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.